Subject: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine
From: Derek from Research Radar <[email-masked]>
To: [email-masked]
Date: Fri, 24 Apr 2026 13:05:46 +0000
List-Id: <derekpruski.substack.com>

View this post on the web at https://derekpruski.substack.com/p/eli-lillys-quintuple-agonist-the

Let’s talk about one of the biggest stories currently brewing in the obesity and metabolic disease space — Eli Lilly’s rumored quintuple agonist. If you’ve been on peptide Twitter, Reddit, or Instagram the last few weeks, you’ve seen the hype. Animal data reportedly dropping at ADA on May 29, 2026. Five receptors hit by a single molecule. The next step beyond retatrutide.
I want to walk through what’s actually going on here, because there’s real, exciting science behind this AND there’s a lot of social media buzz that’s getting mashed together. The mechanism is fascinating, the trajectory of the field is remarkable, and calcitonin in particular could solve problems nobody has solved yet.
This post is going to cover what a quintuple agonist actually is, why the field is moving in this direction, what each of the five receptors does, what’s confirmed versus what’s hype, and why time is the most important variable in all of this. Grab a coffee.
As always, this is research use only. Nothing here is medical advice.
═══════════════════════════════
WHAT IS A QUINTUPLE AGONIST?
A quintuple agonist is a single molecule engineered to activate five different receptors in the body simultaneously. To understand why that matters, you need to understand one key concept first.
An agonist is a compound that activates a receptor. Think of receptors like switches on the surface of your cells — an agonist walks up and flips the switch ON, which triggers whatever that switch controls. Appetite, blood sugar regulation, fat burning, satiety, and so on.
Here’s the progression of how this field has evolved:
Semaglutide (Ozempic, Wegovy) activates 1 receptor (GLP-1)
Tirzepatide (Mounjaro, Zepbound) activates 2 receptors (GLP-1, GIP)
Retatrutide activates 3 receptors (GLP-1, GIP, glucagon)
A quintuple agonist would activate 5 receptors in one molecule
Each generation has meaningfully outperformed the last. Semaglutide produces around 15% weight loss. Tirzepatide pushed that to around 22.5% at 72 weeks. Retatrutide hit 28.7% at 68 weeks in its Phase 3 trial. The idea behind the quintuple is to stack even more metabolic pathways into a single dose and push efficacy into territory that previously only bariatric surgery could reach.
═══════════════════════════════
THE FIVE RECEPTORS AND WHY EACH MATTERS
The rumored Lilly quintuple reportedly targets GLP-1, GIP, glucagon, amylin, and calcitonin. Let’s break down what each one actually does.
GLP-1 (Glucagon-Like Peptide-1)
This is the backbone of every modern weight loss drug, from semaglutide forward. GLP-1 stimulates insulin release when blood sugar is high, suppresses glucagon (preventing unnecessary sugar release from the liver), and slows gastric emptying so you feel full longer. It also acts directly on the brain’s appetite centers in the hypothalamus, reducing hunger and food reward signaling. This is why semaglutide alone can drive 15% weight loss — GLP-1 is incredibly powerful on its own.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
For decades, GIP was considered a “bad” hormone because it was associated with fat storage. Tirzepatide flipped that narrative. It turns out that when you activate GIP alongside GLP-1, you get significantly better weight loss AND better tolerability with less nausea. GIP enhances insulin sensitivity, supports GLP-1’s appetite effects, and appears to help the body handle nutrients more efficiently. The synergy between GLP-1 and GIP is why tirzepatide outperformed semaglutide so dramatically.
Glucagon
This is the “burn fat for fuel” switch. Glucagon receptor activation increases energy expenditure — meaning your body burns more calories at rest — promotes fat breakdown in the liver and adipose tissue, and improves lipid profiles and liver health. The tricky part is glucagon also raises blood sugar, which is why you can’t use it alone. But when you pair it with GLP-1 and GIP (which both lower blood sugar), the net effect is a metabolic powerhouse — you’re suppressing appetite AND torching calories at the same time. This is why retatrutide has shown such strong results in fatty liver disease (MASLD) in addition to weight loss.
Amylin
Amylin is a hormone your pancreas releases alongside insulin after meals. It complements the incretin effects through a different pathway:
Slows gastric emptying through a distinct mechanism from GLP-1
Reduces glucagon release after meals
Acts on the brain to promote satiety
Tends to have better tolerability than incretins, with less nausea
Lilly’s eloralintide (a selective amylin agonist) showed up to 20.1% weight loss at 48 weeks in Phase 2 — as a standalone drug. Novo Nordisk’s CagriSema combines semaglutide with an amylin agonist for this exact reason. Amylin is a proven target.
Calcitonin
This is the most interesting addition, and the one most worth understanding in depth.
Calcitonin is a hormone your thyroid produces that’s been known for decades primarily for calcium regulation and bone health. But over the last 10-15 years, researchers have discovered it has major metabolic effects. Here’s why stacking it matters:
Works with amylin but through different selectivity. Amylin and calcitonin activate receptors in the same family but hit them with different profiles, so stacking them gives broader, more sustained satiety signaling than either alone. This is the logic behind DACRAs (Dual Amylin and Calcitonin Receptor Agonists) like KBP-042 and KBP-089, which showed stronger weight loss and glucose control than pure amylin agonists in preclinical and early human trials.
Improves insulin sensitivity. Calcitonin receptor activation improves insulin sensitivity in muscle and fat tissue through a different pathway than GLP-1 or GIP. Complementary mechanisms stacked, not duplicated.
Potential bone protection, which is huge. Rapid weight loss from drugs like retatrutide and tirzepatide causes meaningful bone density loss. It’s a known side effect of losing weight fast, regardless of how you do it. Calcitonin’s classical role is protecting bone by inhibiting bone resorption. A calcitonin component could theoretically offset that bone loss, which would be a massive clinical advantage.
Possible cartilage protection. Early evidence suggests calcitonin receptor activation has anti-inflammatory and cartilage-protective effects, particularly relevant given retatrutide’s strong knee osteoarthritis data. Could be a natural fit for that indication.
So calcitonin isn’t just “bonus satiety.” It’s potentially the piece that solves some of the biggest unsolved problems with the current generation of weight loss drugs.
═══════════════════════════════
WHY THE FULL STACK MAKES SENSE
When you look at what each receptor brings to the table in the rumored quintuple, the design philosophy becomes clear:
GLP-1 and GIP give core appetite and blood sugar control (the tirzepatide backbone)
Adding glucagon brings fat-burning and energy expenditure (the retatrutide upgrade)
Adding amylin brings extended satiety and slowed gastric emptying from a different pathway
Adding calcitonin brings longer-duration satiety, insulin sensitivity, and bone/joint protection
On paper, you’d be combining the best of everything that’s already working. The incretin backbone of tirzepatide, the glucagon fat-burning of retatrutide, and the amylin/calcitonin satiety plus bone protection of the DACRA class — all in one molecule. The mechanism makes sense, which is a big part of why people are excited.
═══════════════════════════════
WHAT’S CONFIRMED VS. WHAT’S HYPE
Here’s where I want to pump the brakes a little.
The Lilly Quintuple Story (Mostly Hype Right Now)
The version circulating on X, Reddit (r/GLP1ResearchTalk), and Instagram reels claims Lilly is unveiling animal data on a GLP-1/GIP/glucagon/amylin/calcitonin quintuple at ADA Scientific Sessions on May 29, 2026.
The reality check:
No official Eli Lilly press release exists for this compound
No pipeline entry exists on Lilly’s public pipeline page
No named compound (no LY-number) has been disclosed
The buzz traces back to a handful of social media accounts that got amplified
That doesn’t mean it’s fake. Lilly doesn’t announce preclinical assets until they have data in hand, so it’s entirely plausible something drops at ADA. They already own amylin chemistry through eloralintide, and they’ve proven they can design unimolecular polyagonists. The pieces are there.
But “plausible” is not the same as “confirmed.”
The Other Quintuple That’s Real (And Worth Knowing About)
There’s a second quintuple in the literature that’s already published, and it proves the concept works in principle.
It was presented at EASD 2025 in Vienna by Dr. Daniela Liskiewicz from Helmholtz Zentrum München. That molecule targets GLP-1 + GIP + pan-PPAR (alpha, delta, gamma — three PPAR isoforms = five total targets). It uses a clever delivery mechanism where the PPAR part is only released inside cells that express GLP-1 or GIP receptors, so it’s targeted rather than systemic.
Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both weight and glucose control.
This is academic preclinical work — not owned by Lilly, not in human trials — but it demonstrates that pushing past three receptor targets is a legitimate and productive research direction. Different compound, same direction of travel.
═══════════════════════════════
THE CURRENT LANDSCAPE — WHAT’S ACTUALLY IN TRIALS
To keep perspective on where the quintuple fits in, here’s what’s actually advancing right now.
Retatrutide (Triple Agonist)
The most advanced next-generation obesity drug currently in human trials.
TRIUMPH-4 (Phase 3, December 2025): 28.7% weight loss at 68 weeks on the 12mg dose, vs. 2.1% for placebo. Also delivered 76% improvement in WOMAC knee pain scores.
TRANSCEND-T2D-1 (Phase 3, March 2026): Up to 2.0% A1C reduction and 16.8% weight loss at 40 weeks in type 2 diabetes patients
7 additional Phase 3 readouts expected throughout 2026
Likely 2027 FDA approval per GlobalData forecasts
Notable safety signal: dysesthesia in 20.9% of patients on the 12mg dose
Eloralintide (Amylin Agonist)
Lilly’s selective amylin agonist, building the case for amylin as a standalone and combination target.
Phase 2 (November 2025): 9.5% to 20.1% weight loss at 48 weeks
Phase 3 enrollment planned by end of 2025
Being evaluated both as monotherapy and complementary to incretin therapy
Orforglipron (Oral GLP-1)
Lilly’s small-molecule oral GLP-1 agonist, approved in April 2026 under the name Foundayo.
First oral GLP-1 that can be taken without food or water restrictions
ATTAIN-1 Phase 3: 12.4% weight loss (27.3 lbs) at 72 weeks at the 36mg dose
FDA approved for obesity in April 2026 — fastest NME approval since 2002
This is the actual current pipeline. The quintuple, if it’s real, sits well behind all of these.
═══════════════════════════════
WHY TIME IS THE KEY VARIABLE
Here’s what matters most for anyone following this story. The excitement is warranted, but the timeline is not short.
If animal data drops at ADA in 5 weeks, that’s mouse data. From mouse preclinical to approved human drug is historically 8-12 years. Even in this accelerated environment, we’re talking years before any of this matters clinically.
Retatrutide itself isn’t approved yet. It has seven more Phase 3 readouts coming in 2026, with likely 2027 FDA approval. The triple agonist is the story of the next 12-18 months. The quintuple is the story of the early 2030s at the earliest.
Many preclinical compounds never make it to humans. The history of drug development is full of animal models that looked amazing and then failed in translation. We should expect that possibility with any new molecule.
The dysesthesia signal in retatrutide — the abnormal sensation side effect that appeared in 20.9% of patients on the highest dose — shows that even well-designed polyagonists can surface new safety signals when they hit humans. More receptor targets means more potential for unexpected interactions. That’s a real consideration for the quintuple concept.
═══════════════════════════════
A NOTE FOR THE RESEARCH PEPTIDE COMMUNITY
I already know what’s coming — people are going to start searching for “quintuple agonist” on vendor sites after this buzz.
Don’t waste your time. If you see one listed, it’s fake. There’s no public sequence, no structure, nothing to verify against. Anyone claiming to have a quintuple right now is selling you vibes.
The research peptide market always follows clinical science with a lag:
Retatrutide is only now becoming broadly available because the sequence has been public for years
Tirzepatide took time after Phase 2 data came out
Any real quintuple — even if Lilly announces something verifiable in May — wouldn’t be meaningfully accessible in the research space for a long time
Anything claiming to be a quintuple before that is a scam
═══════════════════════════════
BOTTOM LINE
The progression from dual to triple to quintuple is one of the most exciting trajectories in modern metabolic medicine.
What makes the quintuple concept interesting:
Each receptor in the rumored stack solves a distinct problem
The mechanisms are complementary, not redundant
Calcitonin specifically could address issues nobody has solved yet — bone density loss from rapid weight loss, durability of appetite suppression, and joint protection
The trajectory of the field supports the idea that more targets, carefully combined, can push efficacy higher
What to keep in mind:
The Lilly quintuple is currently social media buzz, not confirmed pipeline
Even if animal data drops at ADA in 5 weeks, it’s still mouse data
Mouse-to-market is typically 8-12 years
Retatrutide is what’s actually arriving soon
Eloralintide is what’s actually advancing through Phase 3 for amylin
The quintuple, if real, is a late-decade story
The most important thing to do right now is stay curious and stay patient. Let the science play out. Don’t build expectations around compounds that haven’t even had human trials yet. I’ll cover whatever drops at ADA on May 29 when it happens.
═══════════════════════════════
KEY REFERENCES (FOR DEEPER READING)
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526
Eli Lilly. Retatrutide TRIUMPH-4 Phase 3 results press release. December 11, 2025. investor.lilly.com
Eli Lilly. Retatrutide TRANSCEND-T2D-1 Phase 3 results press release. March 19, 2026. investor.lilly.com
Eli Lilly. Eloralintide Phase 2 results press release (published simultaneously in The Lancet). November 2025
Liskiewicz D, et al. GLP-1R/GIPR/Pan-PPAR quintuple agonist presentation. EASD 2025 Annual Meeting, Vienna
Medscape coverage: “Novel Quintuple Agonist for Weight Loss, Glucose Control?” September 29, 2025. medscape.com
News-Medical coverage: “New quintuple agonist shows promise for treating obesity and type 2 diabetes.” September 21, 2025. news-medical.net
Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various publications
Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/research-development/pipeline
═══════════════════════════════
For research use only. Not intended for human consumption or medical use. Always consult qualified professionals regarding any health-related decisions.

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOVE0wTlRJek9Dd2lhV0YwSWpveE56YzNNRE0yTWpVekxDSmxlSEFpT2pFNE1EZzFOekl5TlRNc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lkl0eHdHOVNPaG1CWFVwVzBTMmJQVEdyaHJ4Z3ZxZTl5SzduNkJzd2p6MVkiLCJwIjoxOTUzNDUyMzgsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc3MDM2MjUzLCJleHAiOjIwOTI2MTIyNTMsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.e3xiSUyxo0jWGtG2CT6rurhnKyXFEWDUCL3Loq7N76c?